Latest Share Purchase Plan News

Australian Strategic Materials has closed its Share Purchase Plan substantially oversubscribed, raising nearly four times its target to accelerate key growth projects including US expansion and ramping up its Korean Metals Plant.

AIC Mines has delivered strong FY25 production and financial results while securing key contracts and financing to expand its Eloise processing plant and advance the Jericho copper deposit development.

Scalare Partners has raised $3 million through a share placement to fund its acquisition of Tank Stream Labs, alongside a $1.08 million Share Purchase Plan for existing shareholders. This capital raise aims to bolster Scalare’s position in the flexible workspace and tech investment sectors.

Pacific Edge Limited has opened a $5 million Share Purchase Plan at $0.10 per share, conditional on shareholder approval of a prior $16.1 million Placement. The capital raise aims to extend the company’s cash runway and accelerate US market adoption of its bladder cancer diagnostic tests amid Medicare non-coverage.

FireFly Metals reports exceptional infill drilling results at its Green Bay Copper-Gold Project, confirming strong mineral continuity and setting the stage for a resource upgrade and mining feasibility studies.

Pacific Edge Limited (ASX – PEB) has announced a securities purchase plan (SPP) aiming to raise up to NZD 5 million, contingent on shareholder approval of a prior NZD 16 million placement. The move is designed to bolster working capital amid ongoing growth initiatives.

Dreadnought Resources has fortified its balance sheet with an $8.5 million capital raise and secured a $15 million joint venture with Teck Resources, advancing its Mangaroon gold and critical minerals projects.

Imugene Limited has launched a $37.5 million equity raising through a Placement and Share Purchase Plan, offering new shares and options to fund its pivotal azer-cel clinical program. The raise includes attaching and piggyback options, subject to shareholder approval, aiming to bolster the company’s immuno-oncology pipeline.

Imugene Limited has launched a A$37.5 million capital raising to advance its promising off-the-shelf CAR T therapy, azer-cel, following encouraging Phase 1b data showing a 75% overall response rate in lymphoma patients.

Imugene Limited has completed a $22.5 million institutional placement and launched a $15 million Share Purchase Plan, both featuring attaching options, to fund its azer-cel clinical program through a pivotal trial in 2026.

Hawsons Iron Limited has successfully raised $1.91 million through an oversubscribed Share Purchase Plan and a targeted Placement, positioning the company to fast-track key project studies and environmental assessments.

Warriedar Resources has announced a landmark mineral resource upgrade at its Ricciardo deposit, now home to Australia’s largest open-pit antimony resource, alongside significant gold discoveries and a successful A$21 million capital raise to accelerate exploration.